18F-MFBG

Phase 2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson Disease (PD)

Conditions

Parkinson Disease (PD), Lewy Body Dementia (LBD)

Trial Timeline

Nov 30, 2025 → Jul 30, 2026

NCT ID

NCT07176286

About 18F-MFBG

18F-MFBG is a phase 2 stage product being developed by Illumina for Parkinson Disease (PD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07176286. Target conditions include Parkinson Disease (PD), Lewy Body Dementia (LBD).

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease (PD) were approved

Approved (20) Terminated (3) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Lemborexant + placeboEisaiApproved

✅Safinamide MesilateEisaiApproved

✅Istradefylline PillKyowa KirinApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07176286	Phase 2	Recruiting	Nov 30, 2025	Jul 30, 2026	Parkinson Disease (PD)
NCT06233903	Phase 2	Withdrawn	Jan 1, 2025	Dec 1, 2025	Neuroblastoma
NCT04724369	Phase 3	Completed	Nov 18, 2021	May 1, 2024	Neuroblastoma

Competing Products

20 competing products in Parkinson Disease (PD)

See all competitors

Product	Company	Stage	Hype Score
exidavnemab + Placebo Comparator	BioArctic AB	Phase 2	36
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
LY4006896 + Placebo	Eli Lilly	Phase 1	36
ATH-1017 + Placebo	LeonaBio	Phase 2	17
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
Mirabegron + Placebo	Astellas Pharma	Approved	43
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
Equfina 50 mg	Eisai	Pre-clinical	26
Equfina	Eisai	Pre-clinical	26
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
Safinamide Mesilate	Eisai	Approved	43
E2007 + E2007 + E2007	Eisai	Phase 2	35